|

Lupus Clinical Trials in New York, NY

30 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseasePhase 1<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3<1 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 1<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2<1 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)—<1 mi
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyPhase 2<1 mi
Safety and Efficacy of ONT01 in LupusEarly 1<1 mi
VIBRANT: VIB4920 for Active Lupus NephritisPhase 2<1 mi
Alnuctamab for Refractory SLE (LATTE Study)Phase 1<1 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/2<1 mi
IMPACT Study: IMProve Pregnancy in APS With Certolizumab TherapyPhase 2<1 mi
Effects of Stopping Hydroxychloroquine in Elderly Lupus DiseasePhase 3<1 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 3<1 mi
Safety of the Herpes Zoster Subunit Vaccine in LupusPhase 4<1 mi
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132Phase 4<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 2<1 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPhase 1/2<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPhase 2<1 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseasePhase 1<1 mi
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)—<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants—5 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 45 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPhase 29 mi
Transforming Care for Individuals With Childhood-onset Systemic Lupus ErythematosusN/A12 mi
Trial of Belimumab in Early LupusPhase 417 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 250 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.